ACTR3 enhances the hyperproliferation of psoriatic keratinocytes by activating the TAK1 ‐ MK2 ‐ HSP27 pathway
The FEBS Journal · 2026
DOI: 10.1111/febs.70558 ↗At a glance
Journal article in The FEBS Journal, 2026. Written by Jianxiao Xing and 7 co-authors. Institution: Peking University First Hospital Taiyuan Hospital, Shanxi Key Laboratory of Stem Cells for Immunological Dermatosis, State Key Breeding Laboratory of…. Major MEDLINE topics: Psoriasis, Keratinocytes, MAP Kinase Kinase Kinases, Intracellular Signaling Peptides and Proteins. 49 references. Funded by: Applied Basic Research Project of Shanxi Province, China, National Natural Science Foundation of China.
Abstract (original language)
Psoriasis is a chronic immune‐mediated skin disorder characterised by abnormal keratinocyte proliferation and cutaneous inflammation. ACTR3 (actin‐associated protein 3) is significantly overexpressed in both cutaneous malignant tumours and psoriatic keratinocytes, and is recognised as a potential key nodal molecule linking tumours to inflammatory skin conditions. Lysine 2‐hydroxyisobutyrylation (Khib)—a critical post‐translational modification—exerts regulatory effects on the pathogenesis of various diseases; however, its specific role in psoriasis pathogenesis remains elusive. In this study, we demonstrated that elevated ACTR3 expression in cutaneous tumours and psoriasis promotes abnormal keratinocyte proliferation in psoriasis. Khib‐modified protein profiles in epidermal tissues from psoriatic patients and healthy controls were analysed, leading to the identification of ACTR3 as a differential target protein. Results showed that Khib modification levels at the K42 site of ACTR3 were significantly reduced in lesional tissues from psoriatic patients and imiquimod (IMQ)‐induced psoriatic mice. Further validation using ACTR3 K42A mutation experiments confirmed that decreased Khib modification at this site exacerbates IMQ‐induced psoriatic inflammation and keratinocyte proliferation. Deacetylases Sirt1 and HDAC1 were found to reduce ACTR3 Khib modification levels, thereby regulating ACTR3 expression and subsequent keratinocyte (KC) proliferation. Additionally, signalling pathway analysis revealed that downregulated K42‐Khib modification of ACTR3 enhances keratinocyte proliferation by activating the TAK1‐MK2‐HSP27 pathway. Notably, TAK1 antagonists effectively reversed abnormal keratinocyte proliferation and psoriatic inflammation induced by the ACTR3 K42A mutation. This study elucidates that reduced Khib modification at the ACTR3 K42 locus promotes keratinocyte proliferation via regulation of the TAK1‐MK2‐HSP27 signalling pathway, offering a previously undescribed molecular insight into psoriasis pathogenesis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Peking University First Hospital Taiyuan Hospital, Shanxi Key Laboratory of Stem Cells for Immunological Dermatosis, State Key Breeding Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Ch…
- Taiyuan Second People's Hospital, China.
ORCID profiles: Jianxiao Xing, Kaiming Zhang
Funding
- Applied Basic Research Project of Shanxi Province, China
- National Natural Science Foundation of China
Cite
APA
Xing, J., Li, J., Wang, Y., Liang, Y., Yao, Y., He, Y., Niu, X., & Zhang, K. (2026). ACTR3 enhances the hyperproliferation of psoriatic keratinocytes by activating the TAK1 ‐ MK2 ‐ HSP27 pathway. The FEBS Journal. https://doi.org/10.1111/febs.70558
Vancouver
Xing J, Li J, Wang Y, Liang Y, Yao Y, He Y, et al. ACTR3 enhances the hyperproliferation of psoriatic keratinocytes by activating the TAK1 ‐ MK2 ‐ HSP27 pathway. The FEBS Journal. 2026. doi:10.1111/febs.70558
BibTeX
@article{Xing2026,
author = {Xing, Jianxiao and Li, Junqin and Wang, Ying and Liang, Yanyang and Yao, Yuanjun and He, Yali and Niu, Xuping and Zhang, Kaiming},
title = {ACTR3 enhances the hyperproliferation of psoriatic keratinocytes by activating the TAK1 ‐ MK2 ‐ HSP27 pathway},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70558}
}
EUVIMED